Vaccine

Significant advancements and a fifteen-month extension for the RBDCOV project

2024

The European Commission has granted a fifteen-month extension to continue with the RBDCOV Project. So far, 240 volunteers have been recruited across all the centres set to join adolescents’ clinical trial (named HH3) to test the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine in adolescents aged 12 to 17.

The European Commission has granted a fifteen-month extension to the RBDCOV project,

Read More

Significant advancements and fifteen month extension for the RBDCOV project

2024

The European Commission has granted a 15-month extension to the RBDCOV project, allowing researchers additional time to recruit volunteers for the HH-3 clinical trial. This trial assesses the efficacy, tolerability, and safety of the BIMERVAX® COVID-19 vaccine as a booster shot in adolescents aged 12 to 17.

The project, led by Vall d’Hebron University Hospital, has seen encouraging progress with over 240 volunteers already enrolled. To achieve the target of 300 participants,

Read More

Science4Pandemics initiatives to educate young people on pandemic preparedness

2023

Science4Pandemics (S4P) is an EU-funded project that aims to educate young people on how to prevent future pandemics through a game-based learning approach.

S4P needs your support!

S4P is dedicated to young people, and they need your help to reach them! The video game, the webinars, the questionnaires: have a look below at what S4P is working on and help them reach thier audience by sharing this news with your colleagues,

Read More

Study reveals moderate effectiveness of Pfizer-BioNTech’s Covid-19 vaccine against Omicron in children aged 5-11

2022

A large study on the effectiveness of the Pfizer-BioNTech’s Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.

The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London.

This is one of the first large observational studies that uses Real-World Data evaluate the effectiveness of the Pfizer-BioNTech BNT162b2 (Comirnaty) vaccine in children aged 5-11 against the Omicron variant.

Read More

🇬🇧 Study reveals moderate effectiveness of Pfizer Covid-19 vaccine against Omicron in children aged 5-11

2022

Padua, 30 June 2022 – A large study on the effectiveness of the Pfizer Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.

The study was conducted at Israel’s largest healthcare organization, Clalit Health Services, in collaboration with researchers from the University of Padua, Harvard University and University College London.

Read More

🇬🇧 European RBDCOV project to study HIPRA’s COVID-19 vaccine in children adolescents and immunocompromised patients

2022

Funded by the Horizon Europe programme, RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the different variants of COVID-19 using a recombinant protein.                

 

RBD Dimer recombinant protein vaccine against SARSCoV2” (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA.

Read More

Johnson & Johnson has planned trials of its vaccine that will include infants.

2021

Johnson & Johnson plans to test its coronavirus vaccine in infants and even in newborns, as well as in pregnant women and in people who have compromised immune systems.

The bold plan for expanded clinical trials met with the approval of Dr. Ofer Levy, director of the Precision Vaccines Program at Harvard’s Boston Children’s Hospital and a member of the Food and Drug Administration advisory committee that reviewed the company’s vaccine data.

Read More

Prof. Timo Vesikari talks to us about COVID-19 vaccines and children

2021

In December 2020 Penta held its annual Scientific Meeting. Despite the unusual get together due to COVID-19, we shared great science together. Among the experts invited was Timo Vesikari, a vaccine specialist who provided an insightful overview of the current scenario around COVID-19 vaccine development. He agreed to an interview with us and shed some light on our understanding of COVID-19 vaccines and how they impact children.

Read the interview here

Read More